Advances in Immunotherapy for Metastatic Melanoma
Featured Topic Information:
Continuing Medical Education Information
Date of Original Release: April 4, 2012
Instructions For Participation
To receive a maximum of 0.75 AMA PRA Category 1 Credits™ for this activity:
To receive up to 0.75 CNE credits for this activity:
This activity is directed toward surgical oncologists, general surgeons, oncology nurses, medical oncologists, dermatologists, and other healthcare professionals who treat or screen for melanoma.
Statement Of Need
Melanoma kills 1 person every hour in the United States. It is a devastating disease with a rising incidence. Melanoma is the most common cancer in women age 25 to 29, is the number one cancer killer of women age 30 to 35, and takes the greatest toll of all cancers on women and men in terms of average years of life lost, because it afflicts young patients to such a great extent.
Management of melanoma remains challenging for all members of the health care team. Assessing risk, getting patients into the healthcare system, evaluating prognostic information, choosing appropriate therapy, working as a team, and educating, guiding and motivating the patient remain challenging. While many healthcare providers are exposed to patients with the potential for melanoma, a core group of specialists are most knowledgeable about the optimal management of this malignancy. These specialists will be the ones to interpret the new information gathered from ongoing research and studies, and to provide suggestions on how to incorporate new treatments into existing disease management algorithms.
Upon proper completion of this activity, participants should be better able to:
For reading resources related to this activity, click here
Accreditation And Credit Designation
The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Each physician should claim only the credit commensurate with the extent their participation in the activity.
0.75 contact hours of Continuing Nursing Education will be granted by The University of Pittsburgh Medical Center (UPMC). UPMC is an approved provider of continuing nursing education by the Pennsylvania State nurses Association (PSNA), an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Disclosure Of Commercial Support
We gratefully acknowledge an educational grant from Bristol-Myers Squibb and Merck in support of this activity.
Contributing Faculty & Disclosures
In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
John M. Kirkwood, MD (Chair)
Jedd D. Wolchok, MD, PhD
UPMC Center for Continuing Education in the Health Sciences/Melanoma Care, LLC staff members have no financial conflicts to disclose.
Independent peer reviewer has no financial conflicts to disclose.
Melanoma Care, LLC
©Melanoma Care, 2012, except where noted. This webcast may not be reproduced in whole or part without the express written permission of Melanoma Care, LLC.
This CME program represents the views and opinions of the individual faculty for each case and does not constitute the opinion or endorsement of the editors, the advisory board, the publishing staff, Melanoma Care, the UPMC Center for Continuing Education in the Health Sciences, UPMC/University of Pittsburgh Medical Center or affiliates, or University of Pittsburgh School of Medicine.
Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions, including without limitation, FDA-approved uses, and any off-label uses.